Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014646
Filing Date
2024-11-06
Accepted
2024-11-06 16:30:55
Documents
69
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20240930x10q.htm   iXBRL 10-Q 1874676
2 EX-31.1 acrs-20240930xex31d1.htm EX-31.1 15625
3 EX-31.2 acrs-20240930xex31d2.htm EX-31.2 15666
4 EX-32.1 acrs-20240930xex32d1.htm EX-32.1 9583
  Complete submission text file 0001558370-24-014646.txt   7923072

Data Files

Seq Description Document Type Size
5 EX-101.SCH acrs-20240930.xsd EX-101.SCH 41311
6 EX-101.CAL acrs-20240930_cal.xml EX-101.CAL 44771
7 EX-101.DEF acrs-20240930_def.xml EX-101.DEF 198388
8 EX-101.LAB acrs-20240930_lab.xml EX-101.LAB 438251
9 EX-101.PRE acrs-20240930_pre.xml EX-101.PRE 311703
72 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20240930x10q_htm.xml XML 1598943
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 241431538
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)